Neuromod startup IVEAcare raises $27.5M, names CEO
Minneapolis-based neuromodulation technology developer iVEAcare announced today that it raised $27.5 million in a Series A financing round.
Minneapolis-based neuromodulation technology developer iVEAcare announced today that it raised $27.5 million in a Series A financing round.
In the Research Article “Size, distribution, and vulnerability of the global soil inorganic carbon” (12 April 2024, p. 233), the background of Fig. 4A features…
Learn how the Deloitte Health Equity Institute is translating purpose into action to advance health equity.
Human visual recognition is remarkably robust to chromatic changes. In this work, we provide a potential account of the roots of this resilience based on…
There was much excitement in the press and in the psychiatric research community recently as a flurry of papers was p…
Nature – Technique wipes away tags on DNA that must be reprogrammed during development of reproductive cells.
HSE issued advice to passengers on board Ryanair flight between Gatwick and Dublin last Thursday
After $50 million upgrade, U.S. sub can reach 99% of the ocean floor
Artificial skin mimics the sensory feedback of biological skin
Nature Nanotechnology – The ability to genetically modify haematopoietic stem cells would allow the durable treatment of a diverse range of genetic disorders but gene…